NOXXON Pharma N.V. ( ALNOX.PA) Stock. Should you Buy or Sell? $ 0.04
0.00 (-2.50 %)
NOXXON Pharma N.V. Analysis
Updated on 08-08-2022
|52 Week Range
||$0.038 - $0.4098
NOXXON Pharma N.V. opened the day at $0.04 which is -2.50 % on yesterday's close.
NOXXON Pharma N.V. has a 52 week high of $0.4098 and 52 week low of $0.038, which is a difference of $0.3718.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $3.05 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy NOXXON Pharma N.V. for $3.05 M, it would take 15 years to get your money back. NOXXON Pharma N.V. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
1 D | All
NOXXON Pharma N.V. Stock Forecast - Is NOXXON Pharma N.V. a Buy or Sell?
|DCF Score||Strong Buy|
|PE Score||Strong Sell|
Growth and Value
|Net Profit Margin
Valuing NOXXON Pharma N.V.
|Price Book Value Ratio
||Price To Book Ratio
|Price To Sales Ratio
||Price Earnings Ratio
How liquid is NOXXON Pharma N.V.
||Debt Equity Ratio
|Long Term Debt To Capitalization
||Total Debt To Capitalization
Latest news about NOXXON Pharma N.V.
About NOXXON Pharma N.V.
CEO : DR. Aram Mangasarian
Sector : Healthcare
Industry : Biotechnology
Website : https://www.noxxon.com
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.